Unrealistic expectations for duodenoscope fuelled Ambu's overuse of funds
When Britt Meelby Jensen took charge of the Danish medtech company early last year, she immediately saw a situation that had to be turned around.
by ulrich quistgaard, translated by daniel pedersen
Enormous expectations was why Danish medtech company Ambu invested so heavily in duodenoscope, said Chief Executive Officer Britt Meelby Jensen at the company’s capital markets day on Wednesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Ambu mulling over capital raise
For subscribers
DNB Markets: Ambu is a classic "turnaround case"
For subscribers
Professor rebuts Ambu's explanation for slow Russia exit
For subscribers
